Figure 9.

ADP inhibition via apyrase reduces glomerular accumulation of leukocytes but not platelets. A: Effect of apyrase treatment on anti-GBM antibody-induced glomerular platelet accumulation. Mice were treated with the ADP-metabolizing enzyme apyrase (0.2 U/g, i.v., n = 6) before administration of anti-GBM antibody, and glomerular platelet adhesion was assessed using intravital microscopy as for previous experiments. Data were compared with mice treated with anti-GBM antibody alone (n = 6). Data are shown as mean ± SEM. B: Effect of apyrase treatment on anti-GBM antibody-induced glomerular leukocyte accumulation. Mice were treated with NSG, anti-GBM antibody alone, or anti-GBM antibody and apyrase (as above), and glomerular leukocyte adhesion was assessed using intravital microscopy. Data show leukocyte adhesion two hours after administration of either NSG, anti-GBM antibody alone, or anti-GBM antibody in apyrase-pretreated mice (n = 6 per group). Data are shown as mean ± SEM. **P < 0.05 versus NSG-treated mice, and *P < 0.05 versus anti-GBM antibody-treated mice.